Progen Pharmaceuticals Ltd Granted Muparfostat (PI-88) patent in Europe
19 May 2010. The Directors of Progen Pharmaceuticals Limited (ASX:PGL, NASDAQ :PGLA) today
announced the granting of a European patent for the Preparation and Use of Sulfated Oligosaccharides which
includes Muparfostat (PI-88).
Progen Pharmaceuticals Limited has an exclusive worldwide license to this technology and recently announced a
Non Binding Letter of Intent to sublicense this to Medigen Biotech.Corp.
Historically, PI-88 was the result of a fully funded research collaboration with Professor Chris Parish’s group at
the John Curtin School of Medical Research at The Australian National University (ANU).
The patent number is 0837683. The applicant for the patent is the Australian National University. The term of the
patent is 20 years from the date of application - April 1996, and will expire in April 2016.
Muparfostat (PI-88) is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-
cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on
inhibition of two biological processes — angiogenesis (the growth of new blood vessels) and metastasis (the
spread of cancer to other sites) — critical to the growth and progression of cancer.
“Europe is a major pharmaceutical market and the granting of this patent provides additional coverage in this
important market,” said Sue MacLeman, Chief Executive Officer, Progen Pharmaceuticals Ltd.
About Progen Pharmaceuticals Ltd
Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, development and
commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a
focus and strength in anti-cancer drug discovery and development. Progen targets the multiple mechanisms of
cancer across its three technology platforms of angiogenesis, epigenetics and cell prolif